B
NXTC icon

Bailard’s NextCure NXTC Stock Holding History

Bailard’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,550
Closed -$149K – 763
2022
Q1 		$149K Buy
+2,550
New +$160K 0.01% 683

Other funds holding NXTC

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bailard's NXTC Position: Q2 2022 in Review

Bailard sold out of NextCure (NXTC) in Q2 2022, closing a stake of 2,550 shares — an estimated $149K sold.

Bailard first reported a position in NXTC in Q1 2022 and held it in 1 quarter. The position peaked at $149K in Q1 2022. 51 funds tracked by Wall St. Rank hold NXTC as of Q2 2022.

  • Bailard reported no remaining NextCure position as of Q2 2022 after selling out during the quarter.
  • Bailard sold 2,550 NextCure shares in Q2 2022, an estimated $149K.
  • Bailard first reported a position in NextCure in Q1 2022 and held it in 1 quarter.
  • Bailard's NextCure position peaked at $149K in Q1 2022.
  • 51 funds tracked by Wall St. Rank held NextCure as of Q2 2022.

Based on Bailard's 13F filing for Q2 2022, filed 27 Jul 2022.